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Identity 
Other names: INDOL1; INDO2; Proto-IDO 






The human IDO2 gene is encoded by 10 exons 
spanning 81,437 bps at chromosome 8p11.21 
(nucleotides 39,911,631-39,993,067).  
 
 
A: Structure of human IDO2 gene and transcripts. Complete coding region is 1260 bps encoding a 420 aa polypeptide. Alternate splice 
isoforms lacking the exons indicated are noted. Hatch boxes represent a frameshift in the coding region to an alternate reading frame 
leading to termination. Black boxes represent 3' untranslated regions. Nucleotide numbers, intron sizes, and positioning are based on 
IDO sequence files NW_923907.1 and GI:89028628 in the Genbank database. 
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The murine IDO2 gene is similarly sized but localized 
to a syntenic locus on mouse chromosome 8A2. The 
IDO1 and IDO2 genes are present tandemly in a tail-to-
head arrangment on chromosome 8 in humans and 
mice. In lower vertebrates such as zebrafish and toa s 
only a single IDO gene may be present that may be 
more IDO2-like in structure. This closer relationship to 
IDO2 suggests that IDO2 may actually be the ancestor 
of the better characterized IDO1 gene, and that IDO1 
might have been generated by gene duplication of 
IDO2 before the origin of tetrapods in mammalian 
evolutionary history. Two single nucleotide 
polymorphisms (SNPs) that occur commonly in the 
coding region human IDO2 gene have been 
characterized. These SNPs are discussed further below 
in the Protein Function section. 
Transcription 
Transcription of IDO2 gene produces multiple mRNA 
messages of which the first characterized was 1,260 bp 
in length. At least two transcripts are expressed with 
alternate 5' exons, suggesting that the IDO2 gene may 
have multiple promoter regions. Exon 1A of the IDO2 
gene contains the start codon for a full-length protein; 
the trans-cript(s) containing exon 1B does not have n 
in-frame start codon at a similar position. On the other 
hand, transcripts containing exon 1B have a more wide-
spread expression pattern than those contain-ing exon 
1A that encode full-length proteins. Start codons i 
exon 3 exist that have a Kozak consensus sequence that 
are conserved in an alignment of all vertebrate IDO 
proteins, thus, these codons may potentially be used to 
generate NH2 terminally-truncated IDO2 proteins. The 
IDO2 gene encodes least 4 alternatively spliced 
transcripts that lack various patterns of exons (exons 3, 
4, 5, 6, and 8) from within the full-length coding 
sequence. The IDO2 promoter contains a prominent 






Full-length IDO2 encodes a protein of 420 amino acids 
with an approximately calculated molecular weight of 
45 kDa. The size of this IDO2 protein is slightly larger 
than full-length IDO1 protein. 
Expression 
IDO2 is expressed in a variety of antigen-presenting 
cell types consistent with the notion that it functions as 
an immunomodulatory gene like IDO1. Human IDO2 
mRNA is detected in liver, small intestine, spleen, 
placenta, thymus, lung,  
brain, kidney, and colon. In mice, IDO2 is 
predominantly expressed in the kidney, followed by 
epididymis, testis, liver, ovary, uteris, and placenta. In 
mouse epididymis, IDO2 is expressed in the tails of 
spermatozoa while IDO1 is expressed in the principal 
and apical cells of the caput epididymis. In mouse 
kidney, IDO2 is expressed only in the tubules while 
IDO1 is expressed primarily in blood vessels. The 
expression patterns of IDO1 and IDO2 suggest the 
possibility of functional non-redundance. 
Localisation 
Indirect immunofluorescence studies suggest that IDO2 
protein has a predominantly cytoplasmic localization. 
Biochemical studies suggest there may be some 
differences in localization compared to the cytoplasmic 
IDO1 protein, based on the greater ease of extracting 
IDO1 compared to IDO2 from cells. 
Function 
IDO2 is a presumptive immunomodulatory gene based 
on its close structural relationship to IDO1 and its
expression in a variety of antigen-presenting cell types. 
Both IDO1 and IDO2 will catabolize tryptophan to 
kynurenine. Biochemical studies indicate that both 
enzymes are similarly robust in catabolic activity, 
although the in vitro conditions required for IDO2 to 
manifest the same level of activity differ somewhat 
from IDO1. However, whether IDO2 is active as a 
tryptophan catabolizing enzyme in human dendritic 
cells has been disputed. Further work is needed to 
conclusively determine that IDO1 and IDO2 are similar 
in their preference for substrates and reaction pathw ys 
to generate product. 
A non-redundant function for IDO2 relative to IDO1 is 
suggested by their rather distinct expres-sion patterns 
and response to extracellular stimuli. For example, 
IDO1 is strongly induced by interferon-gamma (IFNG) 
but it is less clear this is the case for IDO2. 
Additionally, whereas IDO1 is induced in endothelial 
cells during malaria infection in mice, IDO2 is induced 
in kidney, downregulated in liver, and unlike IDO1 
independent of the presence IFN-g. Both IDO and 
IDO2 catabolize tryptophan, trigger phosphorylation of 
the trans-lation initiating factor eIF2a, and mobilize 
translation of LIP, an inhibitory form of the immune 
regulatory transcription factor NF-IL6/ CEBPb that is 
upregulated by amino acid deprivation. However, 
whereas tryptophan resto-ration switches off the LIP 
induction pathway when it is activated by IDO1, LIP 
induction is not switched off when it is activated by
IDO2. Together, this information suggests that IDO1 
and IDO2 produce somewhat distinct signaling path-
ways, suggesting distinct functions in immuno-
modulation. 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(2) 151 
 
B: Amino acid alignment of IDO and IDO2. Amino acids determined by mutagenesis and the crystal structure of IDO that are critical for 
catalytic activity are positioned below the human IDO sequence. Two commonly occurring SNPs identified in the coding region of human 
IDO2 are shown above the sequence which alter a critical amino acid (R248W) or introduce a premature termination codon (Y359stop). 
 
Two single nucleotide polymorphisms (SNP) that 
produce non-conservative changes in the coding region 
have been characterized that abolish catalytic activity. 
One SNP is a C-T transition that causes the amino acid 
change R248W. Based on knowledge of the related 
IDO protein, the R248W change is predicted to abolish 
a critical contact in the catalytic site that contacts the 
indole ring of tryptophan, the presumptive substrate. 
Experimen-tal data confirm that this SNP abolishes 
tryptophan catabolic activity. The other SNP is a T-A 
transversion that produces the premature stop codon 
Y359STOP. Experimental data confirm that this SNP 
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also abolishes tryptophan catabolic activity. The 
R248W alteration is highly represented in individuals 
of European descent. The Y359STOP alteration is 
highly represented in individuals of Asian descent. 
Neither SNP is as prevalent in individuals of African 
descent. Individuals with one of these inactivating 
alleles might display alterned immune function relative 
to individuals with a wild-type allelic configuration. 
In biochemical assays, IDO2 exhibits preferences 
distinct from IDO1 for inhibition by the well-studied 
IDO inhibitor 1-methyl-D,L-tryptophan (1MT). 
Specifically, the levo stereoisoform L-1MT 
preferentially inhibits IDO1 activity whereas the dxtro 
stereoisoform D-1MT preferentially inhibits IDO2. 
Interestingly, in preclinical models D-1MT has been 
observed to exhibit greater antitumor activity compared 
to L-1MT, prompting the hypothesis that IDO2 may 
contribute to tumoral immune escape like IDO1. 
However, since IDO is genetically required for the 
activity of D-1MT the biochemical mechanisms 
underlying 1MT action are likely to be complex. 
Nevertheless, results of in vitro biochemical 
experiments suggest that L-1MT preferentially blocks 
IDO1, with little effect on IDO2, whereas D-1MT 
preferentially the IDO2, with little effect on IDO1. 
Homology 
Human IDO has 62% identities (77% similarities) with 
mouse IDO, and 44% identities (64% similarities) with 
mouse IDO2. Human IDO2 has 72% identities (84% 
similarities) with mouse IDO2 and 45% identities (65% 
similarities) with mouse IDO. Human IDO has 44% 
identities (63% similarities) with human IDO2 and 








While limited information exists as yet, two lines of 
information have suggested a possible link between 
IDO2 and cancer. First, recent work has identified 
IDO2 expression in human tumors, including gastric, 
colon, renal, and pancreatic tumors. 
Immunohistochemical analysis performed in pancreatic 
tumors reveals IDO2 expression both at the level of the 
tumor cell as well as immune cells in tumor-draining 
lymph nodes. However, IDO2 expression and 
tryptophan catabolizing activity in  
human tumor cells and antigen-presenting cells has 
been disputed. Second, the apparent selectivity of IDO2 
for inhibition by the D stereoisomer of 1MT, which 
tends to be more active in a variety of biological assays 
for IDO function, including in antitumor assays, 
suggests that IDO2 may be important to sustain 
immune escape and growth of tumors. Knockout mice 
that have become available recently will be important 
for establishing the these suggested roles for IDO2 in 
cancer. 
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